Suven Pharma has turned ex-bonus from September 25, 2020 pursuant to the board approval granted for the issue of bonus shares in its meeting held on September 16, 2020. The record date for the same has been fixed as September 28, 2020. The board has recommended the issue of bonus shares in proportion of one bonus share (face value of | 1 each) for every equity share held (i.e. 1:1). Consequently, the share price has changed to | 369/share from | 738/share. Accordingly, our target price has also been revised to | 385/share from | 770/share earlier. After the recent run up, the...